GlassScriptPhysician profile
Olmer Brooker
NPI 1952304297
$1,678.55
in general payments reported to CMS, 2019-2025
28 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $240 · 2021: $415 · 2022: $155 · 2023: $189 · 2024: $134 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $197.66 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Merck Sharp & Dohme LLC | $130.93 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $126.20 | 2020-2021 | |
| Pfizer INC. | $119.42 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.35 | 2020-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $110.97 | 2019-2021 | |
| Amarin Pharma, INC. | $109.26 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $90.64 | 2019-2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $76.67 | 2022-2023 | Eliquis |
| Abbvie INC. | $68.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.03 | 2019-2025 | Airsupra |
| Radius Health, INC. | $58.32 | 2019-2022 | |
| Novo Nordisk INC | $56.59 | 2019-2024 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.68 | 2019-2023 | |
| Abbott Laboratories | $45.18 | 2022-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $30.90 | 2023 | |
| Novartis Pharmaceuticals Corporation | $26.18 | 2019 | |
| Seqirus USA INC | $24.92 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $24.35 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $22.76 | 2019 | |
| Amgen INC. | $20.58 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $17.95 | 2022 | |
| Genentech USA, INC. | $15.85 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.46 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.87 | 2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $14.66 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $14.43 | 2020 | |
| Allergan, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olmer Brooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.